[18F]Florbetapir SUVR analytical method. Flowchart showing acquisition methods (purple), image processing (blue), and outcomes (green). PET positron emission tomography, MRI magnetic resonance imaging, GM gray matter, WM white matter, CSF cerebrospinal fluid, FWHM first width half maximum, ROI region of interest. (TIFF 2485 kb
Figure S1. Coomassie blue staining of the SDS PAGE gels containing the microdissected tissue lysates...
Supplementary methods and safety summary. PET imaging parameters and summary of safety findings. (PD...
Figure S4. Clustering analysis of experimental groups and individual cases. Clustering analysis and ...
Table S1. List of SNPs within each set. Table S2. R epistasis results (first 15 lines). Table S3. Tu...
Figure S2. Total protein fluorescent signal from blots used for immunoblot analysis. Total protein l...
Figure S1. SUVR longitudinal analysis. SUVR at week 69 compared to SUVR at baseline using different ...
Figure S3. FDG PET. FDG PET SUVR change from baseline in the low-dose SC (A) and high-dose IV (B) co...
Figure S1. Grey matter volume reduction in the Alzheimer’s disease group (n = 39) compared to health...
Additional file 1: Table S1. PET acquisition and reconstruction information on included patients. Ta...
Table S1. Demographics and clinical characteristics of subjects studied (FACEHBI [29]) for FBB-PET s...
Figure S2. 18F-flortaucipir in CBS 18F-flortaucipir images and corresponding single-subject w-score ...
Figure S1. Qualitative immunohistochemical staining for CSF1R receptor (red) in mouse brain cortex s...
Receiver operator characteristic (ROC) analysis of regional histometric measures and standard retent...
Table S1. Characteristics of the primary antibodies, immunohistochemistry conditions and expression ...
Figure S2. Scatter plots for FBB-PET global SUVR and Aβ plasma ratios in SCD subjects. Correlations ...
Figure S1. Coomassie blue staining of the SDS PAGE gels containing the microdissected tissue lysates...
Supplementary methods and safety summary. PET imaging parameters and summary of safety findings. (PD...
Figure S4. Clustering analysis of experimental groups and individual cases. Clustering analysis and ...
Table S1. List of SNPs within each set. Table S2. R epistasis results (first 15 lines). Table S3. Tu...
Figure S2. Total protein fluorescent signal from blots used for immunoblot analysis. Total protein l...
Figure S1. SUVR longitudinal analysis. SUVR at week 69 compared to SUVR at baseline using different ...
Figure S3. FDG PET. FDG PET SUVR change from baseline in the low-dose SC (A) and high-dose IV (B) co...
Figure S1. Grey matter volume reduction in the Alzheimer’s disease group (n = 39) compared to health...
Additional file 1: Table S1. PET acquisition and reconstruction information on included patients. Ta...
Table S1. Demographics and clinical characteristics of subjects studied (FACEHBI [29]) for FBB-PET s...
Figure S2. 18F-flortaucipir in CBS 18F-flortaucipir images and corresponding single-subject w-score ...
Figure S1. Qualitative immunohistochemical staining for CSF1R receptor (red) in mouse brain cortex s...
Receiver operator characteristic (ROC) analysis of regional histometric measures and standard retent...
Table S1. Characteristics of the primary antibodies, immunohistochemistry conditions and expression ...
Figure S2. Scatter plots for FBB-PET global SUVR and Aβ plasma ratios in SCD subjects. Correlations ...
Figure S1. Coomassie blue staining of the SDS PAGE gels containing the microdissected tissue lysates...
Supplementary methods and safety summary. PET imaging parameters and summary of safety findings. (PD...
Figure S4. Clustering analysis of experimental groups and individual cases. Clustering analysis and ...